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and injury. Conclusion: LMWH given systemically or locally, with or without
iontophoresis did not limit neointimal thickness in this stent model. This result
suggest that clinical triala of LMWH may be similarfy negative.
D97363 Predictors of Terget Vesssl ReveecularizstionFollowing Coronary Stent Deployment
K.M. Ziada, M.H. Kim, W. Potts, A.C. De France, P.L.Whitlow, S.G. Ellis,
S.E. Nieeen, E.M. Tuzcu. The Cleveland Clinic Foundation, C/eve/and,
Ohio, USA
Objective: We aought to determine the clinical, angiographic and ultrasound
predictors of target vessel revascularfzation (lVR) after coronary stenting.
Mathods: All ‘patients who underwent ultrasound-guided 1 or 2 stent
implantation over a 14 month period were included in this atudy. Clinical
and angiogrephic date were prospectively colleeted in a dedicated database.
Intravascular ultrasound analysis of the stented aegments was performed in
a core laboratory. Patients were followed for TVR over 8.0+ 2.4 months.
Resu/ts: Of 239 consecutive study patients, TVR was performed in 32
(13%). No clinieel characteristics or rkskfactors were predictive of TVR. The
effects of other variables on the probability of TVR follows:
Odds Rstio 95%C.I.
(Per 1 SD)
AngicgrephicVariables
Decreasingreference diameter 1.6 1,1-2.6
Increasingbaseline % diamsterstenosis 1.7 1.1-2.5
Increasingbaaeiine lesion length 1.5 1.1-2,5
Distalflowat baseline -=TIMI3 5.0 1.7-14
Ostial locationof Issions 2.9 1.1-7.5
Dewessingflnal YOdiamefarstenoeis 1.2 0.85-1.8
FinalLfftrasoundVariables
Decreasingminimumstent Ium%ndiamster 2.1 1A-3.3
Decreasingminimumstent lumen area 2.2 1.4-3.8
Dacreaaingfinal ‘h diamslerstenoeis 1,1 0.78-1.7
Dacressingfinal 0/0area stenosis 1.3 0.88-1.9
Conclusions.’ Pre-intervention angiographic variablea, particularly TIMI
flow and oetial location, predict TVR. Post-stent percent atenosie by an-
giography or ultrasound do not impact outcome. However, absolute in-stent
lumen area, measured by ultrasound, is an important determinant of TVR.
D97364 Influence of Lesion Length on Late AngiographicOutcome and Restenotic Process After Successful
Stent Implantation
N. Hameeaki, H. Noeaka, T. Kitnura, Y. Nakagawa, H. Yokol, T. Tamura,
M. Nobuyoshi. Kokurs Memorial Hospital, Japan
The purpose of the preeent study waa to investigate the influence of lesion
length on late angiographic outcome and restenoais proceasafter successful
atent placement. The etudy population compriaed 461 consecutive Iesiona
implanted native arteries at elective aituation (Palmez-Schatz stent 401,
Cordis stent 50) and satisfactory angiographic analysie before, after stenting
and 3 or6 rnonthefollow-up (FUP) in a single center (Feb. 199&Feb. 1995).
Total occlusion at baseline and follow-up were excluded. The patients were
divided into 3 groups according to lesion length and following variables were
compared.
Lesioniength 1) <7.5 mm 2) 7.5-14.9 mm 3)2 15.Om P
No. of lesion 145 255 51
No. of stent 1.0 * 0.2 1.0* o 1.3+ 0.5 <OLIOO1
Veeeeisize(mm) 3.22 4c0.58 3.21 kO.54 3.20+0.85
MLD pre(mm) 0.94+0.38 0.83*0.38 0.77* 0.40 0.0JJ6
MLD poet(mm) 2.95+0,38 2.89 & 0.42 2.77+ 0.51 0.03
Acute gain (mm) 2.01 + 0.48 2.08 +0.48 2.00+ 0.47
MLD FUP(mm) 2.15+ 0.68 2.06+0.71 1.80+ 0.75 0.009
Latelose(mm) 0.80&0.80 0.83+0.59 0.97* 0.75
Raafenoaia(50%s) 15% 207. 31% 0.01
No:number,MLD:MinimalLumenDiameter.
Late angiographic outcome auch as MLD at follow-up and binary reeteno-
eis rate correlated closely with lesion length. Leeion length was found to be
exert a significant positive effect on late Ioasbut not in acute gain by univari-
able and multivariable (p c 0.001) analysis. The relative gairrloes relationship
within the groups showed that it vary with the lesion length (group 1) r. loss=
0.31 r. gain+ 0.08, group 2) y = 0.23x + 0.11, group 3) y = 0.48x + 0,01). In
conclusion, lesion length itself influence on both late angiographic outcome
and restenosie process. One should be carefully weighed in selection of the
patients.
1973-651 Are ACC/AHALeeionCheracteristicsPredictivefor
Late Angiographic Results After Coronary Stent
Plecsment?
H. SchOhlen,J. Hausleiter, S. Elezi, A. Wehinger, H. Walter, J. Direchinger,
A. Schdmig. Deutsches Herzzentrum Mtinchen, Garman~ Mediziniacha
Klinik, TechnischaUnivereitat, Munich, Genrrany
ACC/AHA lesion characteriatice describe the complexity of etenosee to pre-
dict the outcome after PTCA. This retrospective study analyzes the quantita-
tive angiographic 6-month follow-up (FU) of 588 Ieeions in 529 patients with
eucceesfulcorona~ stent placement (p-values ae calculated by ANOVA).
A (n = 30) B1 (n= 49) B2 (n =204) C (n = 305) p
MLD pre (mm) 0.86 + 0,67 0.79+ 0.34 0.60+ 0.53 0.68 +0.46 <0,05
RD pre (mm) 2.98 + 0.67 2.96+ 0.50 3.06+ 0.57 3.04 +0.56 na
Number of stenta 1.3 l 0.5 2,5 +2.0 2.6+ 1.5 3.0 + 1.6 <0.05
Ballootieaael 1,10 +0.13 1.12 +0.14 1.11 + 0.19 1.15 +0.17 ne
Acute gain (mm) 2.07+0.54 2.12 + 0S3 2.43+0.65 2.37+0.82 <0.05
MLD post(mm) 2.93+ 0.56 2.91 + 0.46 3.03+0.50 3,05+ 0.33 na
RD post (mm) 2.96+ 0.58 3.05 + 0.51 3.17+ 0.49 3.17* 0.057 na
MLD FU (mm) 2.19+ 1,00 1.96+ 0.60 2.06+0.92 1.90 l 0.91 na
RD FU (mm) 3.01 + 0.61 2.92+ 0.57 3.03+ 0.54 3.05 +0.56 na
Late loss(mm) 0.73 + 0.80 0.95+ 0.83 0.97+ 0.61 1.15 +0.83 <0.05
Restenosisrste 23,3% 20,4% 22.6% 31.8”A na
Cone/usions:Thedifferences in acute data refkscttheACC/AHAgrading of
stenoees.Late Iosaiesignificantly higher in complex stenoses with a trend for
higher restenosis rates. Theee data euggeet that Iesiona of high ACC/AHA-
grading also have a poorer long-term angiographic outcome after scenting.
1973-661Long-Ter~clinica,outcomeein’’~ow-R,s~’’and
“High-Risk” Patients Undergoing Coronary Stent
Implantation
M.K. Hong, G.S. Mintz, J.J. Popma, K.M. Kent, A.D. Pichard, L.F. Satler,
T. Bucher, A. Greenberg, K. Morgan, T. Weaver, K. Donovan, M.B. Leon
Washington Hospital Centac Washington, DC, USA
Previously we ehowed that low-risk pta undergoing “optimal” Palmez-Schatz
stent implantation (ultrasound guidance and 216 atm adjunct PTCA) with
reduced antieoagulation (aspirin andticlopidine only) had excellent acute and
long-term outcomee. To determine the outcomes in “high risk” pte, defined
es (1) auboptimal implantation (poor apposition or incomplete expenaion),
(2) Z3 atente, or (3) thrombus @ Ieaion site (or peri-infarction), treated with
extended anticoagulation (aepirin, ticlopidine, and Lovenox’” for2 weeka), we
asseaeed early and late (>6-month) clinical events in a consecutive seriea
of 1322 native coronary and SVG Palmaz-Schafz stent pta.
Native Coronaries SVG’e
Low-risk High-risk Low-risk High-risk
(N =417) (N-= 547) (N= 134) (N-=224)
MC/SAT (%) 0.7/0.6 0.9/0.2 0.7/0.7 0.9/0.4
TLR (“A)‘ “’ 11.7 19.3* 14.3 11.2
Re-PTCA (“A) 8.5 13.0” 9.1 7.6
CABG (“A) 3.6 7.1* 5.7 4.4
MC= major implications (death, Ml, CABG); SAT = subacutethrombosis;TLR = target
I&ion reveacutarization;” p <0.05 vs. low-riskgroup.
/n conchsion: After ultrasound guided stent implantation, (1) both low-
and high-rfek groups had excellent acute outcomea, but (2) high-risk native
coronary pts had aignificently greater TLR.
1973-671 CliniCelandAngiOgraPhic Restenosi~ After
Coronary Stenting. Incidence and Predictors
J.J.AlonSO,J.M. Dur~n, F. Gimeno, J. Bermejo, L Garcimatrin, L. Fuente,.
J.C. Mufloz, F. Femandez-Avilea. Hospital Universitario, Va//ado/id,Spain
To assess the incidence and predictors of restenosi8 (R) after coronary
stenting (CS), we studied the evolution of 415 stented Iesiona from 373
consecutive pts (61 + 10 yr, 87% male). A total of 469 stents (Palmaz-
Schatz: 93% Wiktor: 7%) were implanted (1.13 stentilesion). In 63% of pts,
PTCA was done due to unetable angina. Indications for CS were: restenosie
14%, “bail-out” 31%, suboptimal result 6%, and “de novo” lesions 49%. The
left anterior descending artery was the most frequently stented (54%).
Angiographic follow-up (FU) at 6 months was done in 940/. of iesions.
Clinical FU was completed in 94Y0of pte. Angiographic R (>50% criterion,
QCA)occurred in23%of lesions (Cl 957.: 19-28%) but only 35 pts developed
angina (clinical R: 11%, Cl 95%: 8-15%). Univariate analysis of 33 clinical,
angiographic and procedural variables showed that type C lesions (p= 0.04),
number of stents per lesions (p = 0.02), diabetes (p = 0.02), minimal Iuminal
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diameter (MLD) pra-PTCA (p = 0.02) and MLD post-CS (p = 0.03) were
related to restenosis. Multivariate analysis (logistic regression) identified the
presenee of diabatee (odds ratio [OR]: 3.5, Cl 95%: 1.4-6.1), number of
stenta par Ieaion (OR 3.1, Cl 95%: 1.2-7.4) and MLD post-CS (OR 0.3, Cl
95%: 0.1+.6) as independent pradietors of R.
Thus: 1) Despite the baseline unfavorable characteristicsof this sample,
a low rate of clinical and angiographic Rafter CS was observed; 2) MLD after
CS, number of stenta per lesion and diabetes were identified as independent
pradietots of restenoais.
1973-681 QuanttitiveAngiographic Pmditiorsof
Reetenoeie efter the Lees Shortening Wellstent
Impientetion
Y.Ozaki, A.G. Violaris, M. Nobuyoshi, H. Yokoi, T. Kobayashi, P.Serruys.
Thoraxcentac Erasmus Uni~, Rotterdam, NL, Dept. of Cardiology Kokuni
Memorial Hospital, Kitakyuayu, Japan, Aichi Medicel lhi~, Nagoya, Japan
The maehanism of stent restenosla still remains unknown. To identify the
arsgiographic predictors of stent restenosis, we performed a retrospective
analysis in 72 patients with the Wallstent implantation and complete set of
quantitative angiographic analysis (pre and post procedure and 6 month
follow-up [fup]). Twenty-one patients (29%) had restenosis (250% diameter
stenosis at fup). Minimal Iuminal diameter (MLD), lesion length and reference
vessel size were measured by QCA system (CAAS 11).Proximal reference
veeael diameter (pmx RD) and distal reference vessel diameter (distal RD)
ware mmpared with Wallstent diameter used (VW diam).
Non-reetenosis Restenosis D-vslus
(51 Patients) (21 patients)
LesionLenoth(mm) 28.8 + 12.1 35.4+ 11.0 <0.05
WSdiem(~m)’
MLD pre (mm)
MLD past (mm)
MLD fup (mm)
prox RD (mm)
dbtel RD (mm)
WS dian!orox RD
WS dlam/distalRD
5.22 * 12.1
0.81 + 0.52
2,s8 * 0,56
2.30 + 0.59
3.45 + 0.69
3.04 k 0.52
1.56 + 0.32
1.76 + 0.36
5,14 * 0.55
0.80 & 0.49
2.42 + 0,51
0.91 * 0.45
3.42 + 0.50
2.37 & 0.57
1.53 + 0.27
2.27 + 0.51
ns
m
<0.05
<0.001
ns
<0,001
ns
<O,wl
Lesion length, MLD post, distal vessel size and the degree of the over-
sizing of Wallstent (compared to distal vessei size) significantly related to
greater Iuminal lose at fup. Diffuse iong iesion in the small distai vessel
may predispose to subsequent restenoais. Operatore should avoid exces-
sive oversizing in the selection of Wallstent and stenting in small distal vessel
to lessen the risk of late restenosis.
PI lntracoron.Y”ltra*..~A~*ssme.t~f~a,,oo.
Angioplasty in Intrastent Reatenoaia
F. Schiele, N. Meneveau, A. Vuillemenot, S. Gupta, D.D. Zhang,
J.-P. Baaaand. H6pital Universitaire Saintdacques, 25000 Besan~on,
France
Optimal treatment of restenosis occurring after coronary stenting, is not yet
clear even if balloon angioplaety (PTCA) has been demonstrated safe and
efficient. The mechanism of balloon angioplasty in intrastent restenosis was
studied with Quantitative Coronary Angiography (QCA) and Intra Coronaw
Ultra Sound (ICUS) in20 Pte.All Ptsweredilatad with a noncompliant balloon
inflated at high pressure (=-15atm), QCA and ICUS data were available for
ail Pta at stent implantation (basal), before and after repeat (PTCA). Minimal
Lumen Diameter (MLD) was assessed with QCA, and vessel size (EEM),
etent cross sectional area, Lumen area and the neo intimal tissue area (Stent
area -Lumen area) with ICUS.
Bessl Before RePTCA RePTCA
MLD (mm) 2.4+ 0,5 0.7* 0.6 1.9 * 0,7
EEM (mn#) 12.9 &2.6 15.0 * 3.7 15.9+ 3,6
Stsnt ares (mrr#) 7.1 + 1.6 7.9+2.0 6.5+ 1.5
Lumenarea (mr#) 7.1 + 1.6 3.2 & 1.1 5.6+ 1.0
Nan inttieeue (mn#) 3.9* 1.5 3.09 + 1.6
Stent area increased after rePTCA, but most of the naointimal tissue
remained within the stent thus explaining that despite 8tent overexpansion,
MLD and Lumen area were lower after RePTCA than at initial stent implan-
tation (respectively, 2.4 A 0.5 vs 1.9 + 0.7 mm, p c 0.05 and 7.1 + 1.6 vs
5.6 + 1.0 mt#, p < 0.01).
We conclude that the mechanism of balloon angioplasly in intrastent
restenoeis is mainiy overexpansion of the stent, most of the naointimal tissue
remaining within the stent.
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1974-83/ Addition ofaPlateletG@oprotelnlM llaMibitor
to Heparin + Aepirin Decreaaee Ex-Vivo Thrombua
Formation After Percutaneous Coronary
Intervention
G.Dangas, J.J, Badimon, J.A. Ambrose, B.S. Coller, J.T. Fallen,
A.M. Cohen, P.Meraj, R. Hayes, S.K. Sharma, J.D. Marmur. The
cardiovascular hEfitU@, Mount Sinai Medical Cente~ Naw york,A/y USA
Although c7E3 Fab, a Gp llb/llla inhibitor, decreases complications after
PTCA, its effect on thrombus formation in these patients is unknown. To
quantify the antithrombotic effects of standard dose c7E3 Fab, we studied 19
patients (60 + 2 yrs, 75% men) undergoing coronary intewention using an
ex-vivo perfusion chamber. Through a venous eannula, blcmdwaspumped
directly from the patient and circulated, under eontroilsxl rhsologic renditions
of high shear rate simulating mild arterial stenosis (1690 a-l), through a
chamber containing a standard thrombogenic substrate (injured porcine aor-
tic media). Perfusion runs were performed on heparin + aspirin prior to the
procedure in ali patients and then repeated 2 hours after the proesdure on
aspirin + heparin alone (Group 1; n = 10) or on aspirin + heparin + c7E3 Fab
(Group 2; n = 9). To quantify thrombus, chamber specimens were stainad
with trichrome and for fibrinogen and platelet ‘factor 4. The cross-saetionai
area of the thrombus (TA; &m2) was measured on 9 sections par chamber
run with computerized planimetry. TA for each condition as mean + SE:
Group1 Group2 P
TA preprocedure 12526 + 1506 16575 + 1566 NS
TA postprocedure 13953 + 1510 S603 + 930 0.04
p (withingroup) NS <0.001
There was no difference between groups in baseline Hot, platelet oount,
preprocsdure PTT,and periprocedure ACT (291 +23 s).
Conclusion: The addition of c7E3 Fab to heparin + aspirin significantly
decreases the propensity to form thrombus on an injured arterial aurface,
providing an insight into the mechanism by which c7E3 Fab reduces pari-
procedurai complications.
~974-841Economi~Assessmentofp,ate,et~,Y~oprotein
llb/llla Receptor Blockade During Coronary
Intervention in the EPILOG Trial
A.M. Lincoff, D.B. Mark, R.M. Calilf, J.E. Tcheng, S.G. Ellis,
L. Davidson-Ray, K.M. Andere~, G.L. Stoner, E.J. Topol. C/eve/and C/in/c
Foundation, Cleveland, OH, USA
In the 2099 pt EPIC trial, use of abciximab (c7E3 Fab, RaoPro) during
coronary intervention decreased baseline hospitalization cost aasoeiatad
with ischemic complications, but savings were offset by costs of increased
bleeding complications. The subsequent EPILOG trial demonstrated in 2792
pts that hemorrhagic risk associated with abciximab therapy ean be nearly
eliminated by reduction of heparin dosing, Using the Economic Model and
cost data derived from the EPIC trial, in-hospital costs of treatment with
abciximab in the EPILOG trial were estimated.
EPIC (observed$) EPILOG (estimated $)
Plscebo Abciximab Placebo Abciximab
IschemicEvents 15.4% 12.9”/. 13,9”/0 8.0%
Uraent CABG 3.64A 2.4% 1.7% 0.4%
M~or Bleed 3.3”A 10.6% 1.1% 1.10%
BaselineCoet $13,4S4 $13,577 $12,767
AbciximabCost
$12,260
$1407 $1407
in-HospCost $13,43; $14,9S4 $12,76; $13,ss7
in-Hosp Difference $1550 $660
F/U Difference ($1270) savings pending
TotalCost perpt $260 pending
in-hospital costs of abciximabtherapy are approximately halved by control
of bleeding risk. Thus, with the heparin regimen from EPILOG, initial data
suggest that abeiximab may incur sufficient cost savings over6 months to pay
for itself. Complete prospectively-collected in-hospital and 6-month madieel
cost data from EPILOG will be presentad.
